Janet L. Stanford
Ph.D., Johns Hopkins University, Epidemiology, 1986.
M.P.H., Emory University, 1982.
B.S., Georgia State University, Nursing, 1980.
The role of environmental, lifestyle and genetic risk factors in relation to cancer etiology, progression and mortality
My main research interests focus on hormonal, environmental, lifestyle and genetic factors that may alter cancer risk, cancer progression, and disease outcomes such as cancer-specific mortality. The role of underlying genetic susceptibility based on rare, and high penetrance mutations as well as more common genetic variants of lower penetrance is a major focus of my research. As a cancer epidemiologist, I have been involved in the development, implementation, and analyses of research studies of the etiology and progression of several different types of cancer, however, my current concentration is on prostate cancer.
The completion of two large population-based case-control studies of risk factors for prostate cancer has allowed us to examine environmental/lifestyle exposures and genetic polymorphisms in candidate genes in relation to prostate cancer etiology and outcomes. Selected results from these studies have shown that: 1) vasectomy is not associated with risk of prostate cancer; 2) higher consumption of cruciferous vegetables, moderate intake of red wine, and regular aspirin use are each associated with reduced risks of prostate cancer; 3) high intensity cigarette smoking increases the risk of prostate cancer; 4) there is an increased risk of prostate cancer among men with a first-degree family history of prostate cancer who carry a specific genetic variant in the CYP17 gene, which is involved in testosterone production; 5) men who are null for the glutathione S-transferase (GST) M1 gene have an increased risk of prostate cancer, particularly among heavy smokers; 6) men who are carriers of BRCA2 mutations have an increased risk of prostate cancer; and 7) genetic variants on chromosome 8q24 are associated with elevated risks of prostate cancer.
We are currently following a large cohort of prostate cancer patients long-term to evaluate how environmental/lifestyle factors and genetic polymorphisms in candidate genes within pathways of interest for prostate cancer as well as single nucleotide polymorphisms (SNPs) identified from genome-wide scans may affect disease progression/recurrence and prostate cancer-specific mortality. Results from these studies indicate that: 1) obesity at the time of prostate cancer diagnosis is associated with over a 2-fold excess risk of adverse outcomes (i.e., progression to metastatic cancer, death from prostate cancer); 2) smoking at the time of prostate cancer diagnosis is associated with adverse patient outcomes; and 3) patients who are treated with androgen deprivation therapy have different outcomes based on genetic variation in the megalin gene, which is involved in androgen transport. Our ongoing studies aim to identify individual SNPs and combinations of genetic variants that may be useful, in addition to standard clinical factors, for better prediction of individual patient outcomes. In addition, we are evaluating how the diagnosis and treatment of prostate cancer affect long-term urinary, sexual and bowel function and general health-related quality of life.
I am principal investigator for the data collection component of the Prostate Cancer Genetic Research Study (PROGRESS), a large family-based study of hereditary prostate cancer. We have enrolled over 300 families with multiple members who have been diagnosed with prostate cancer, some at particularly early ages. Blood samples, baseline and follow-up questionnaires, and medical records are collected on participants. Two genome-wide scans using microsatellite and SNP markers have been completed. Linkage analyses highlighted several regions of interest (e.g., chromosomes 15q, 22q) that we are following up with further studies. We are currently completing a next-generation sequencing project to identify genetic mutation(s) in the 15q linkage region. We are also initiating a whole-exome sequencing project on selected high-risk families with aggressive and/or early onset prostate cancer. The long-term goal of PROGRESS is to identify loci that may contain genes with mutations responsible for hereditary prostate cancer.
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer.. Journal of the National Cancer Institute. 105(10):711-8.. 2013.
Long-term functional outcomes after treatment for localized prostate cancer.. The New England journal of medicine. 368(5):436-45.. 2013.
Consumption of deep-fried foods and risk of prostate cancer.. The Prostate.. 2013.
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.. Human molecular genetics. 22(2):408-15.. 2013.
Reply to circumcision unlikely to be associated with prostate cancer risk.. Cancer. 119(1):246.. 2013.
Association of variants in estrogen-related pathway genes with prostate cancer risk.. The Prostate. 73(12):1-10.. 2013.
Associations of tea and coffee consumption with prostate cancer risk.. Cancer causes & control : CCC.. 2013.
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry.. Nature genetics. 45(6):690-6.. 2013.
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.. Nature genetics. 45(4):385-91,391e1-2.. 2013.
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.. Prostate cancer. 2013:560857.. 2013.
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG.. The Prostate. 72(4):410-426.. 2012.
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families.. BMC medical genetics. 13(1):46.. 2012.
Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.. Cancer epidemiology.. 2012.
Genetic Variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(9):1928-36.. 2011.